ArticleNature communications2020
A nanotrap improves survival in severe sepsis by attenuating hyperinflammation.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Association of preadmission metformin use and prognosis in patients with sepsis with diabetes: a systematic review and meta-analysis.Frontiers in endocrinology · 2026 · on this mapPooled it
- DAMPs, PAMPs, and Alarmins: From Mechanism to Therapy.MedComm · 2026Review
- Artificial exosomes synergistically reshape sepsis immune homeostasis by modulating neutrophil fate and blocking PD-1/PD-L1.Cell reports. Medicine · 2026Article
- The role of immunomodulatory nano systems in the treatment of sepsis: past, present, and future.Nanomedicine (London, England) · 2026Review
- Identification of immune status subtypes and prognostic analysis of septic patients based on Th1/Th2 cytokine assays.Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Telodendrimer nanotrap for selective cytokine removal from sepsis patient plasma.Frontiers in immunology · 2026Article
- Neutrophils loaded NADMaterials today. Bio · 2025Article
- Harnessing Telodendrimer Nanotraps in Nanogels for Systemic Immune Modulation in Sepsis Treatment.ACS pharmacology & translational science · 2025Article
- Lipid nanoparticles fromMolecular therapy. Methods & clinical development · 2025Article
- Quaternized Molecular Brush-Grafted Injectable Microgel with Anti-Inflammatory and Drainage Properties for Efficient Therapy of Anal Fistula.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Nanodrug Delivery Systems for Direct Clearance or Neutralization of LPS.International journal of nanomedicine · 2025Review
- Interaction between endothelial injury and immune response in septic shock: from basic research to clinical applications.Frontiers in physiology · 2025Review
- Alleviating D-Galactose-Induced Aging in Mice by Modulating Gut-Liver Axis UsingFoods (Basel, Switzerland) · 2024Article
- Unveiling cytokine charge disparity as a potential mechanism for immune regulation.Cytokine & growth factor reviews · 2024Review
- Telodendrimer functionalized hydrogel platform for sustained antibiotics release in infection control.Acta biomaterialia · 2024Article
- Development of novel liver-targeting glucocorticoid prodrugs.Medicine in drug discovery · 2024Article
- PAMPs and DAMPs in Sepsis: A Review of Their Molecular Features and Potential Clinical Implications.International journal of molecular sciences · 2024Review
- Engineering Nanotrap Hydrogel for Immune Modulation in Wound Healing.Macromolecular rapid communications · 2023Article
- Micromotor-Enabled Active Hydrogen and Tobramycin Delivery for Synergistic Sepsis Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Bio-Inspired Fractal Robust Hydrogel Catheter for Intra-Abdominal Sepsis Management.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Targeting single mediators has failed to reduce the mortality of sepsis. We developed a telodendrimer (TD) nanotrap (NT) to capture various biomolecules via multivalent, hybrid and synergistic interactions. Here, we report that the immobilization of TD-NTs in size-exclusive hydrogel resins simultaneously adsorbs septic molecules, e.g. lipopolysaccharides (LPS), cytokines and damage- or pathogen-associated molecular patterns (DAMPs/PAMPs) from blood with high efficiency (92-99%). Distinct surface charges displayed on the majority of pro-inflammatory cytokines (negative) and anti-inflammatory cytokines (positive) allow for the selective capture via TD NTs with different charge moieties. The efficacy of NT therapies in murine sepsis is both time-dependent and charge-dependent. The combination of the optimized NT therapy with a moderate antibiotic treatment results in a 100% survival in severe septic mice by controlling both infection and hyperinflammation, whereas survival are only 50-60% with the individual therapies. Cytokine analysis, inflammatory gene activation and tissue histopathology strongly support the survival benefits of treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.